Embrace the Journey of Change
December 3, 2024
Read more
Spravato® (Esketamine) is an FDA-approved nasal spray that is a rapid-acting antidepressant for the treatment of depression.
Get Appointment
If you’ve been battling depression that doesn’t respond to multiple oral antidepressants, Spravato® might be the answer. Specifically designed for adults with Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD), or suicidal thoughts. Adding Spravato® to your current treatment plan could bring the relief you’ve been searching for. Speak with your healthcare provider to explore if this innovative therapy is right for your needs. Above all it's covered by insurance at Penfield Psychiatry.
Request AppointmentSpravato® (Esketamine) is a nasal spray medication endorsed by the U.S. Food and Drug Administration (FDA), specifically designed to treat adults with Treatment-Resistant Depression (TRD) and depressive symptoms in Major Depressive Disorder (MDD) with suicidal thoughts. Unlike traditional oral antidepressants, Spravato® works rapidly, targeting specific brain receptors to restore chemical imbalances, providing relief for those who have not responded to other treatments.
Administered under the supervision of a healthcare provider, Spravato® is part of a comprehensive treatment plan that includes an oral antidepressant. It offers a new approach to managing severe depression symptoms effectively.
Spravato® nasal spray at Penfield Psychiatry Clinic is administered under careful supervision to ensure safety and effectiveness for managing depression symptoms.
Patients should abstain from eating for at least 2 hours and from drinking for 30 minutes before the treatment.
- Gently tilt your head back to a comfortable position.
- Insert the nasal spray device into one nostril and administer two sprays.
- Repeat the process for the other nostril, delivering two sprays.
- Ensure the patient remains in an upright position during and after administration.
- Patients are monitored for a minimum of 2 hours post-treatment.
- Observations are made to manage and address any potential side effects that may arise
- Initially, treatment consists of twice-weekly sessions for the first four weeks.
- This is followed by once-weekly sessions for an additional four weeks.
- Dosage adjustments are made by the doctor based on improvements in the patient’s mental health
Before starting Spravato®, it’s crucial to understand its benefits, risks, and suitability for your health needs. Consult with your healthcare provider to determine if it’s right for you.
At Penfield Psychiatry, we’re committed to making mental health care accessible and affordable. That’s why we partner with a wide range of insurance providers to ensure seamless coverage for our patients.
.png)
-Logo.wine.png){kind=logo}
